Filters:
Investigator: Kevin Yarasheski1 Projects | 1 Researchers | $2,225,237 Invested
2020
C2N Diagnostics
Kevin Yarasheski, PhD
Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology
Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Kevin Yarasheski, PhD
Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology